Patient Info
Welcome to Peptimmune’s patient information area. Our focus is the development of safe and effective immunomodulatory therapies for CNS and autoimmune disorders.
read our patient info in FrenchPlease select from the medical condition or product candidate below:
Multiple Sclerosis Trial Notice — Peptimmune is now Enrolling Patients in France with Secondary Progressive Multiple Sclerosis (SPMS)
Summary:
Peptimmune is studying the safety and proof of pharmacologic mechanism of PI-2301 in patients with Secondary Progressive Multiple Sclerosis (SPMS). This study is being conducted in multiple sites in France and is being led by primary investigator, Professor Gilles Edan, MD (Rennes, France). Approximately forty to fifty patients will be enrolled, and the study is expected to be completed by Q1/2009.
Rationale:
MS is a disease in which the patient's own immune system inappropriately attacks specific proteins located in nerve cells. This damage gives the symptoms of weakness and numbness, among others, commonly seen in MS. PI-2301 is designed to bind to an important receptor on some cells of the immune system, decreasing the immune system's attack on one's nerve cells.
Eligibility and Details:
In this study, people with SPMS between the ages of eighteen and sixty are being randomly assigned to receive either PI-2301 or a placebo weekly. The study will start at an initial dose, enroll patients into that dose cohort, and then progress to the next higher dose. The primary outcomes being measured are safety and other parameters such as immunological markers and MRI scans.
The dosing will occur via a subcutaneous injection given once per week in the clinic.
Contact:
For more information or to find out if you are an eligible SPMS patient, please contact the trial coordinators, Mrs. Meriam Djemai or Mr. Andre Paquin, at Biotrial (Rennes, France), the clinical research organization which is coordinating the study. The phone number is +33-2-9959-9191.
